The SFTPA2 gene helps make surfactant protein A2, a lung protein that helps protect the tiny air sacs from germs and irritation. This gene plays an important role in keeping the lungs working smoothly at their deepest level. If it does not work properly, some people may be more likely to develop lung scarring, ongoing cough, shortness of breath, or, in some families, a higher chance of lung cancer. SFTPA2 is mostly discussed in specialist lung and genetics care rather than in popular media.
What is a gene?
A gene is a stretch of DNA that holds instructions your cells use to make molecules or regulate activities in the body. Some genes carry the information needed to make proteins, which are the working parts of cells. Other genes mainly help control when certain processes happen, where they happen, and how strongly they run. Together, genes affect how the body develops and works, and they can also shape how you respond to food, stress, or medications. More on this topic is available in the LearnHub.
Overview
SFTPA2Gene function
What if the gene works
The SFTPA2 gene helps make surfactant protein A2, a lung protein in the fluid that coats air sacs. It supports easy breathing and helps the lungs clear germs and particles.
Risk
What if the gene does not work
Variants in the SFTPA2 gene can disrupt lung surfactant and cause inherited interstitial lung disease or pulmonary fibrosis, sometimes with lung cancer risk. Milder or more severe variants can affect when symptoms begin and how much scarring develops.
Treatment
What does that mean for your treatment
No SFTPA2-specific treatment or management approach is currently established for people with a pathogenic variant in the SFTPA2 gene. The SFTPA2 gene is being studied as a biomarker in some interstitial lung diseases and lung cancers, but this has not yet changed routine drug choices.
Conditions associated with SFTPA2
Gene function
What if the gene works
Breathing depends on a thin, slippery coating inside the lungs. The SFTPA2 gene helps make surfactant protein A2, which supports this coating and helps protect the tiny air sacs where oxygen moves into the blood. Understanding how the SFTPA2 gene helps the lungs work makes its day to day role easier to picture.
It helps organize surfactant, the slippery material that coats the tiny air sacs in your lungs. This supports smooth opening and closing with each breath.
It helps move, recycle, and clear surfactant after it has done its job. This keeps the lung lining balanced and ready for the next breath.
It can attach to some inhaled germs and particles in the airways. This helps immune cells recognize and clear them as part of normal lung defense.
What is a variant?
A genetic variant is a slight change in the DNA sequence within a gene. These changes are common and help shape normal human diversity, including differences in appearance, metabolism, and the way the body responds to environmental influences. Many variants do not have any noticeable effect and are simply part of natural genetic variation. In some situations, though, a variant can change how a gene functions more significantly and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Pathogenic SFTPA2 gene variants linked to familial pulmonary fibrosis often make the protein fold incorrectly and get trapped inside lung cells instead of being released. This can lower the amount that reaches the air sacs and can trigger cell stress. Some variants have milder effects on folding or stability, while more disruptive variants may cause greater loss of function and are sometimes linked to earlier or more extensive lung disease.
How variants are linked to conditions
Pathogenic variants in the SFTPA2 gene can cause inherited interstitial lung disease, most often familial pulmonary fibrosis. In some families, SFTPA2 gene variants are also linked to a higher chance of lung cancer, especially lung adenocarcinoma. Symptoms and age at onset can vary, even among relatives. These associations are uncommon, but they are well established in human genetics.
A variant is not necessarily a diagnosis
Genetic variants are a routine part of being human and are widely seen across the population. Most do not directly affect health and instead reflect normal human diversity. For many genes, having a variant associated with a condition points to a possible link rather than a clear diagnosis, particularly when several genes and environmental influences play a role. Still, in certain situations, one well-established variant in a particular gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For harmful changes in the SFTPA2 gene, risk is driven mainly by the gene change itself, but smoking can further raise the chance of lung damage and lung cancer. Long-term exposure to lung irritants, such as dusts or fumes, may also affect how lung disease shows up. Regular follow-up can help catch changes early.
Inheritance of SFTPA2 variants
SFTPA2-related conditions are usually inherited in an autosomal dominant pattern. This means a parent with a disease-causing variant in the SFTPA2 gene can pass it on to a child, and each pregnancy has a 50% chance of inheriting that variant. In families asking about the inheritance of SFTPA2 gene variants, the variant can be passed from either mother or father to sons or daughters. Not everyone who inherits an SFTPA2 variant will be affected in the same way, but the inheritance pattern itself is dominant.
What does my SFTPA2 result mean for my family?
A harmful change in the SFTPA2 gene is usually linked to a dominant family pattern, so close relatives such as parents, brothers, sisters, and children may also carry the same change. In practical terms, this can mean more than one person in a family has a history of lung scarring or, in some families, lung cancer. Family members may want to talk with their care team about whether the result is relevant for them.
Genetic information
Genetic testing
How you find out about variants
For families with unexplained lung scarring, genetic testing for SFTPA2 variants usually uses blood, saliva, or a cheek swab. A lab reads the DNA in the SFTPA2 gene and looks for inherited variants, often through a lung disease gene panel or broader sequencing test. Results may show a known variant, no relevant variant, or a result that needs more interpretation.
When should I consider getting a genetic test?
Consider SFTPA2 testing if you or close relatives have scarring lung disease (pulmonary fibrosis), other unexplained long-term lung tissue disease, or a family pattern of these problems, sometimes alongside lung cancer. Testing can help show whether the condition may be inherited and is often discussed with a lung specialist or genetic counselor.
A genetic result is only one part of your health story
Genetic results can provide meaningful insight, although how much they reveal varies by the condition and the specific type of variant. Many factors, including lifestyle, environment, age, and medical history, shape how the body works over time. In some conditions, especially those influenced by many genes, genetic information offers context rather than certainty and is most useful when considered alongside other parts of care. In other situations, a genetic result may give a clear answer. In areas such as medication response, genetic results can also help put individual experiences into perspective.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how your body responds to medicines. Some people break down a drug more slowly or more quickly, while others may be more or less sensitive to its effects. This helps explain why the same treatment can work well for one person, cause more side effects in another, or seem to have less benefit in someone else.
What is Pharmacogenetics?
Pharmacogenetics looks at how differences in genes can shape a person’s response to medicines. It examines the links between genes and drugs to help explain why the same treatment can work differently from one person to another. For many medications, genes affect either how strongly a drug works or how the body processes it. This information can help support treatment decisions that are more informed and more individualized. More detail on this topic is available in the LearnHub.
Drugs influenced by the SFTPA2 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medication choice or response, so questions about side effects, new symptoms, or how your medicines fit with your overall health are best discussed with your doctor.
History
The SFTPA2 gene emerged from lung research in the late 1970s and 1980s, when scientists were separating and naming the proteins found in pulmonary surfactant. Initially understood only through visible traits, later recognized as tied to a specific gene, surfactant protein A was eventually shown to come from two closely related genes, SFTPA1 and the SFTPA2 gene. Building on this early work, scientists mapped these genes to chromosome 10 and clarified their DNA sequence. A major milestone came in 2009, when inherited variants in the SFTPA2 gene were linked to some families with pulmonary fibrosis and lung cancer. That finding gave the gene a clearer place in medical genetics. Since then, research has refined how clinicians interpret rare SFTPA2 variants in affected families.